Organisation paid for research Program year 2025 Source: CMS Open Payments

Neuroscience Research Center LLC

Neither a doctor nor a teaching hospital

Research payments

$5,301,475

225 payments

Through program year 2025, Neuroscience Research Center LLC is reported as receiving $5,301,475 in research payments, across 225 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,520,737 25
2024 Research $528,163 58
2023 Research $1,957,600 73
2022 Research $855,888 21
2021 Research $397,188 26
2020 Research $39,798 21
2019 Research $2,100 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $3,729,797 53 payments
  2. Horizon Therapeutics plc $1,004,393 1 payment
  3. Scilex Pharmaceuticals Inc. $163,252 3 payments
  4. Harmony Biosciences LLC $97,327 32 payments
  5. Averitas Pharma Inc. $74,056 38 payments
  6. GRT US Holding, Inc. $47,476 17 payments
  7. Genentech, Inc. $33,047 7 payments
  8. Otsuka Pharmaceutical Development & Commercialization, Inc. $31,415 4 payments
  9. AbbVie, Inc. $29,091 11 payments
  10. Alnylam Pharmaceuticals Inc. $23,309 7 payments
Studies the money was for Research payments · program years 2019–2025
  1. Long-Term Real-World Comparative Effectiveness of Donanemab Plus Usual Care Versus Usual Care Alone in US Patients With Early Symptomatic Alzheimer's Disease (Trailblazer-Real US) $1,360,143 2 payments
  2. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $1,177,178 8 payments
  3. A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of Vib1116 in Conventional Dendritic Cell (CDC) and Plasmacytoid Dendritic Cell Pdc-Mediated Rheumatic Diseases $1,004,393 1 payment
  4. A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $332,321 2 payments
  5. Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $315,535 6 payments
  6. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Safety and Efficacy of Sp-103 in Subjects With Moderate to Severe Acute Lower Back Pain $163,252 3 payments
  7. Assessment of Safety Tolerability and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $162,158 3 payments
  8. A Donanemab (Ly3002813) Prevention Study in Participants With Alzheimer's Disease (Trailblazer-Alz 3) $95,005 2 payments
  9. Preventive Treatment of Migraine: Outcomes for Patients in Real-World Healthcare Systems (Triumph) $87,975 3 payments
  10. An Interventional Phase III Doubleblind Randomized Controlled Parallelgroup Multisite Clinical Trial Evaluating the Efficacy and Safety of Qutenza in Subjects With Postsurgical Neuropathic Pain $74,056 38 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $163,252 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record